- Home
- TTI vs GLUE Comparison
TTI vs GLUE Comparison
Compare TTI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TTI | GLUE |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TTI | GLUE |
|---|---|---|
| Price | $5.98 | $10.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $11.13 | ★ $26.88 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $8.89 | N/A |
| P/E Ratio | ★ $46.46 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $4.87 | $9.68 |
| 52 Week High | $12.54 | $25.77 |
Technical Indicators
Market Signals| Indicator | TTI | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 45.22 |
| Support Level | $5.64 | $9.69 |
| Resistance Level | $6.31 | $12.00 |
| Average True Range (ATR) | 0.28 | 0.55 |
| MACD | 0.10 | 0.19 |
| Stochastic Oscillator | 85.55 | 54.30 |
Price Performance
Historical ComparisonAbout TTI Tetra Technologies Inc.
Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).